INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 97 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.32 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $266 | -73.4% | 480 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | – | 480 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 480 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 480 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | -50.0% | 480 | 0.0% | 0.00% | – |
| Q3 2021 | $2,000 | +100.0% | 480 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 480 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | +100.0% | 480 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | – | 480 | +42.9% | 0.00% | – |
| Q2 2016 | $0 | -100.0% | 336 | -3.7% | 0.00% | – |
| Q1 2016 | $2,000 | -89.5% | 349 | -85.1% | 0.00% | – |
| Q4 2015 | $19,000 | +533.3% | 2,337 | +593.5% | 0.00% | – |
| Q3 2015 | $3,000 | -88.5% | 337 | -85.5% | 0.00% | – |
| Q2 2015 | $26,000 | -13.3% | 2,326 | +6.8% | 0.00% | – |
| Q1 2015 | $30,000 | -18.9% | 2,177 | +0.2% | 0.00% | – |
| Q4 2014 | $37,000 | – | 2,173 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |